PMID- 17876703
OWN - NLM
STAT- MEDLINE
DCOM- 20090204
LR  - 20220409
IS  - 1573-7217 (Electronic)
IS  - 0167-6806 (Linking)
VI  - 107
IP  - 2
DP  - 2008 Jan
TI  - Recognition and management of treatment-related side effects for breast cancer 
      patients receiving adjuvant endocrine therapy.
PG  - 167-80
AB  - In postmenopausal women with hormone receptor-positive early-stage breast cancer, 
      the use of aromatase inhibitors (AIs) to suppress estrogen is associated with 
      improved clinical outcomes compared with tamoxifen therapy. Women receiving such 
      endocrine therapy may experience treatment-related side effects that negatively 
      affect health-related quality of life (QoL) and adherence to therapy. In 
      published clinical trials and in clinical practice, adverse events (AEs) 
      constitute the main reason for nonadherence to endocrine treatment. Serious AEs 
      are sometimes resolved by switching to a different agent, whereas other side 
      effects can often be managed to allow patients to remain on therapy without 
      sacrificing QoL. Across all adjuvant endocrine trials, regardless of the 
      treatment received, vasomotor symptoms such as hot flashes are the most common 
      side effects. Other frequently reported side effects, such as vaginal discharge, 
      vaginal dryness, dyspareunia, and arthralgia, vary in prevalence between 
      tamoxifen and AIs. Here we provide an overview of reported AEs of adjuvant 
      endocrine therapy, focusing on those that are amenable to pharmacologic or 
      nonpharmacologic management without treatment discontinuation. Also highlighted 
      are specific management strategies that may improve patient QoL and thereby 
      optimize adherence to therapy, which in turn might improve patient outcomes.
FAU - Cella, David
AU  - Cella D
AD  - Center on Outcomes, Research and Education, Northwestern University Feinberg 
      School of Medicine, Evanston, IL 60201, USA. d-cella@northwestern.edu
FAU - Fallowfield, Lesley J
AU  - Fallowfield LJ
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20070918
PL  - Netherlands
TA  - Breast Cancer Res Treat
JT  - Breast cancer research and treatment
JID - 8111104
RN  - 0 (Antineoplastic Agents, Hormonal)
RN  - 0 (Aromatase Inhibitors)
RN  - 094ZI81Y45 (Tamoxifen)
RN  - EC 1.14.14.1 (Aromatase)
SB  - IM
MH  - Antineoplastic Agents, Hormonal/*adverse effects/therapeutic use
MH  - Aromatase/metabolism
MH  - Aromatase Inhibitors/pharmacology
MH  - Breast Neoplasms/metabolism/*pathology
MH  - Chemotherapy, Adjuvant/methods
MH  - Clinical Trials as Topic
MH  - Endocrine System
MH  - Female
MH  - Humans
MH  - Medical Oncology/methods
MH  - Patient Compliance
MH  - Quality of Life
MH  - Surveys and Questionnaires
MH  - Tamoxifen/metabolism
MH  - Treatment Outcome
RF  - 84
EDAT- 2007/09/19 09:00
MHDA- 2009/02/05 09:00
CRDT- 2007/09/19 09:00
PHST- 2007/02/09 00:00 [received]
PHST- 2007/02/12 00:00 [accepted]
PHST- 2007/09/19 09:00 [pubmed]
PHST- 2009/02/05 09:00 [medline]
PHST- 2007/09/19 09:00 [entrez]
AID - 10.1007/s10549-007-9548-1 [doi]
PST - ppublish
SO  - Breast Cancer Res Treat. 2008 Jan;107(2):167-80. doi: 10.1007/s10549-007-9548-1. 
      Epub 2007 Sep 18.